COVID-19-associated lymphopenia

Revision as of 15:53, 13 July 2020 by Ramyar (talk | contribs)
Jump to navigation Jump to search

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

COVID-19 Microchapters

Home

Long COVID

Frequently Asked Outpatient Questions

Frequently Asked Inpatient Questions

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Vaccines

Secondary Prevention

Future or Investigational Therapies

Ongoing Clinical Trials

Case Studies

Case #1

COVID-19-associated lymphopenia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of COVID-19-associated lymphopenia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on COVID-19-associated lymphopenia

CDC on COVID-19-associated lymphopenia

COVID-19-associated lymphopenia in the news

Blogs on COVID-19-associated lymphopenia

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for COVID-19-associated lymphopenia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Oluwabusola Fausat Adogba, MD[2]

Synonyms and keywords:

Overview

Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan, China. On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. There is no established system for the classification regarding COVID-19 related lymphopenia. four hypothetical mechanisms regarding lymphopenia are Direct infection of Lymphocyte, direct destroying of lymphocytic organs, inflammatory cytokines such as TNFɑ, IL-6, Lymphocyte inhibition,

Historical Perspective

  • Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan,China.[1]
  • On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.
  • Since the first descriptive study lymphocyte count has been a marker of interest.[2]

Classification

There is no established system for the classification regarding COVID-19 related lymphopenia.

Pathophysiology

Causes

The SARS-CoV-2 (COVID-19) viral infection is the known cause of lymphopenia in COVID-19 patients. To read more click here

Differentiating COVID-19 related Lymphocytopenia from other Diseases

COVID-19 related Lymphocytopenia starts acutely in the course of the disease, with other manifestations of the disease. Lymphocytopenia, is associated with corticosteroid use, infections with HIV and other viral, bacterial, and fungal agents, Hodgkin's disease, leukemia, malnutrition, systemic lupus erythematosus,[5] high stress levels, whole body radiation, rheumatoid arthritis, and iatrogenic conditions.

In alphabetical order. [6] [7]

Epidemiology and Demographics

  • The incidence of the Coronavirus Disease 2019 (COVID-19) as of June 28, 2020 is approximately 9,843,073 cases worldwide with 495,760 deaths.[8]
  • Patients of all age groups may develop COVID-19. However, the elderly population and immunocompromised individuals are more likely to develop severe cases of COVID-19.

Risk Factors

People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19. These medical conditions include:[9]

Screening

  • Lymphopenia on admission has been associated with predicting the severity of clinical outcomes. Approximately, a three-fold increase in severity has been associated with lymphopenia on admission.[10]
  • A routine CBC with differential can be used for monitoring and predicting disease progression and severity in patients.

Natural History, Complications, and Prognosis

  • Lymphopenia is the most common laboratory finding in COVID-19, and is found in as many as 83% of hospitalized patients.[11]
  • Lymphopenia is lymphocyte count of less than 1.5 × 109/L. It is associated with a 3-fold increased risk of severe COVID-19 infection.
  • Patients with lymphopenia on admission have been associated with poor prognostic outcomes[12]. Recent studies have shown that 85% of severely ill patients have lymphopenia. Futhermore, patients who have died from COVID-19 infection showed significantly lower lymphocyte level than survivors.[13]
  • Common hematologic complications of coronavirus also include neutrophilia and thrombocytosis.

Diagnosis

Diagnostic Choice of Study

Lymphopenia refers to a count of less than 1,000 lymphocytes per microliter of blood in adults, or less than 3,000 lymphocytes per microliter of blood in children.[14] The following tests are used to diagnose lymphopenia:

  • Complete Blood test
  • Flow cytometry

History and Symptoms

Lymphopenia as a result of COVID-19 can present with different symptoms. People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19:[15]

Physical Examination

  • There are no physical findings associated with lymphopenia.
  • However patients with significant lymphopenia can show signs of the associated disorder, in this case COVID-19 symptoms.

Laboratory findings

  • Lymphocyte count on CBC with differential is less than 1.5x109/L is potentially associated with severe outcomes.[10]
  • Peripheral blood smear- This maybe helpful, however there is insufficient evidence recommending routine peripheral blood smear in COVID-19 patients.

Electrocardiogram

There are no ECG findings associated with COVID-19 associated lymphopenia.

X-ray

There are no X-ray findings associated with COVID-19 associated lymphopenia.

Echocardiography or Ultrasound

There are no echocardiography or ultrasound findings associated with COVID-19 associated lymphopenia.

CT Scan

There are no CT scan findings associated with COVID-19 associated lymphopenia.

MRI

There are no MRI findings associated with COVID-19 associated lymphopenia.

Other imaging findings

There are no other imaging findings associated with COVID-19 associated lymphopenia.

Other Diagnostic studies

  • Bone marrow biopsy, although not recommended may be helpful if there is suspision of other disorders that can cause lymphopenia , but there is not enough evidence to support bone marrow biopsy in COVID-19 patients.

Treatment

Medical therapy

Immune-Based Therapy:

  • There are insufficient data to recommend either for or against the use of COVID-19 convalescent plasma or SARS-CoV-2 immune globulins for the treatment of COVID-19.

The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of non-SARS-CoV-2-specific intravenous immune globulin (IVIG) for the treatment of COVID-19, except in the context of a clinical trial. This should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.[16]

  • There are insufficient data to recommend either for or against the use of the following agents for the treatment of COVID-19:
    • Interleukin-1 inhibitors (e.g., anakinra)
    • Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab)

Except in the context of a clinical trial, the Panel recommends against the use of other immunomodulators, such as: Interferons, because of the lack of efficacy in treatment of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and toxicity. Janus kinase inhibitors (e.g., baricitinib), because of their broad immunosuppressive effect.[16]

References

  1. "WHO Western Pacific | World Health Organization".
  2. Ruan, Qiurong; Yang, Kun; Wang, Wenxia; Jiang, Lingyu; Song, Jianxin (2020). "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". Intensive Care Medicine. 46 (5): 846–848. doi:10.1007/s00134-020-05991-x. ISSN 0342-4642.
  3. Fischer, Karin; Hoffmann, Petra; Voelkl, Simon; Meidenbauer, Norbert; Ammer, Julia; Edinger, Matthias; Gottfried, Eva; Schwarz, Sabine; Rothe, Gregor; Hoves, Sabine; Renner, Kathrin; Timischl, Birgit; Mackensen, Andreas; Kunz-Schughart, Leoni; Andreesen, Reinhard; Krause, Stefan W.; Kreutz, Marina (2007). "Inhibitory effect of tumor cell–derived lactic acid on human T cells". Blood. 109 (9): 3812–3819. doi:10.1182/blood-2006-07-035972. ISSN 0006-4971.
  4. Liao, Yuan-Chun; Liang, Wei-Guang; Chen, Feng-Wei; Hsu, Ju-Hui; Yang, Jiann-Jou; Chang, Ming-Shi (2002). "IL-19 Induces Production of IL-6 and TNF-α and Results in Cell Apoptosis Through TNF-α". The Journal of Immunology. 169 (8): 4288–4297. doi:10.4049/jimmunol.169.8.4288. ISSN 0022-1767.
  5. W L Ng, C M Chu, A K L Wu, V C C Cheng, K Y Yuen. "Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus". Quarterly Journal of Medicine. 99 (1): 37–47. doi:10.1093/qjmed/hci155.
  6. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  7. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
  8. "WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard".
  9. "People Who Are at Higher Risk for Severe Illness | Coronavirus | COVID-19 | CDC".
  10. 10.0 10.1 Zhao, Qianwen; Meng, Meng; Kumar, Rahul; Wu, Yinlian; Huang, Jiaofeng; Deng, Yunlei; Weng, Zhiyuan; Yang, Li (2020). "Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis". International Journal of Infectious Diseases. 96: 131–135. doi:10.1016/j.ijid.2020.04.086. ISSN 1201-9712.
  11. "Management of Patients with Confirmed 2019-nCoV | CDC".
  12. Huang, Ian; Pranata, Raymond (2020). "Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis". Journal of Intensive Care. 8 (1). doi:10.1186/s40560-020-00453-4. ISSN 2052-0492.
  13. Fathi, Nazanin; Rezaei, Nima (2020). "Lymphopenia in COVID‐19: Therapeutic opportunities". Cell Biology International. doi:10.1002/cbin.11403. ISSN 1065-6995.
  14. "Lymphocytopenia | National Heart, Lung, and Blood Institute (NHLBI)".
  15. "Symptoms of Coronavirus | CDC".
  16. 16.0 16.1 "Immune-Based Therapy | Coronavirus Disease COVID-19".


Template:WikiDoc Sources